MedPath

Neuronetics

🇺🇸United States
Ownership
-
Employees
203
Market Cap
-
Website
Introduction

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

Clinical Trials

12

Active:1
Completed:7

Trial Phases

2 Phases

Phase 3:1
Not Applicable:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Not Applicable
5 (83.3%)
Phase 3
1 (16.7%)

Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments

Recruiting
Conditions
Depression
OCD
Anxiety Depression
First Posted Date
2025-05-30
Last Posted Date
2025-05-30
Lead Sponsor
Neuronetics
Target Recruit Count
12000
Registration Number
NCT06997549
Locations
🇺🇸

Neuronetics, Malvern, Pennsylvania, United States

Retrospective Analyses of TrakStar Database

Recruiting
Conditions
Depression
Anxiety Depression
Obsessive-Compulsive Disorder
First Posted Date
2025-04-08
Last Posted Date
2025-04-08
Lead Sponsor
Neuronetics
Target Recruit Count
156000
Registration Number
NCT06917339
Locations
🇺🇸

Neuronetics, Malvern, Pennsylvania, United States

A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents

Completed
Conditions
MDD
First Posted Date
2024-11-21
Last Posted Date
2025-01-06
Lead Sponsor
Neuronetics
Target Recruit Count
7690
Registration Number
NCT06699940
Locations
🇺🇸

Neuronetics, Malvern, Pennsylvania, United States

Symptom Evaluation Following Repetitive Transcranial Magnetic Stimulation

Not Applicable
Active, not recruiting
Conditions
Neurologic Symptoms
First Posted Date
2024-05-28
Last Posted Date
2025-05-08
Lead Sponsor
Neuronetics
Target Recruit Count
20
Registration Number
NCT06429748
Locations
🇺🇸

Charlotte Skin and Laser, Charlotte, North Carolina, United States

Retrospective TMS Therapy for Adults With MDD

Completed
Conditions
Major Depressive Disorder (MDD)
First Posted Date
2022-09-15
Last Posted Date
2022-09-15
Lead Sponsor
Neuronetics
Target Recruit Count
6456
Registration Number
NCT05541302
  • Prev
  • 1
  • 2
  • 3
  • Next

News

FDA Approves TMS for Adolescent Depression: Study Shows Significant Symptom Improvement

A recent study analyzed data from over 1,200 adolescents and young adults treated with Transcranial Magnetic Stimulation (TMS) for Major Depressive Disorder (MDD).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.